|
JPH0637520B2
(ja)
|
1985-07-03 |
1994-05-18 |
味の素株式会社 |
ポリペプチド
|
|
JPS63502716A
(ja)
|
1986-03-07 |
1988-10-13 |
マサチューセッツ・インステチュート・オブ・テクノロジー |
糖タンパク安定性の強化方法
|
|
US4973577A
(en)
|
1986-04-04 |
1990-11-27 |
The Salk Institute For Biological Studies |
FSH-releasing peptides
|
|
US5080891A
(en)
|
1987-08-03 |
1992-01-14 |
Ddi Pharmaceuticals, Inc. |
Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US5096815A
(en)
|
1989-01-06 |
1992-03-17 |
Protein Engineering Corporation |
Generation and selection of novel dna-binding proteins and polypeptides
|
|
US5198346A
(en)
|
1989-01-06 |
1993-03-30 |
Protein Engineering Corp. |
Generation and selection of novel DNA-binding proteins and polypeptides
|
|
US5078486A
(en)
|
1989-10-13 |
1992-01-07 |
Evans David W |
Self-calibrating vision test apparatus
|
|
WO1992004913A1
(en)
|
1990-09-13 |
1992-04-02 |
Children's Hospital Medical Center Of Northern California |
Method for increasing red blood cell production by treatment with activin or activin-related peptides
|
|
US5208219A
(en)
|
1991-02-14 |
1993-05-04 |
Celtrix Pharmaceuticals Inc. |
Method for inducing bone growth
|
|
US5118667A
(en)
|
1991-05-03 |
1992-06-02 |
Celtrix Pharmaceuticals, Inc. |
Bone growth factors and inhibitors of bone resorption for promoting bone formation
|
|
JPH06500574A
(ja)
|
1991-05-10 |
1994-01-20 |
ザ ソーク インスティテュート フォア バイオロジカル スタディーズ |
アクチビン／ＴＧＦ―βスーパーファミリーのレセプターのクローニングおよび組換えによる産生
|
|
US6162896A
(en)
|
1991-05-10 |
2000-12-19 |
The Salk Institute For Biological Studies |
Recombinant vertebrate activin receptors
|
|
US5885794A
(en)
|
1991-05-10 |
1999-03-23 |
The Salk Institute For Biological Studies |
Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
|
|
US20050186593A1
(en)
|
1991-05-10 |
2005-08-25 |
The Salk Institute For Biological Studies |
Cloning and recombinant production of CRF receptor(s)
|
|
US6287816B1
(en)
|
1991-06-25 |
2001-09-11 |
Genetics Institute, Inc. |
BMP-9 compositions
|
|
ATE175441T1
(de)
|
1991-06-25 |
1999-01-15 |
Genetics Inst |
Bmp-9 zusammensetzungen
|
|
US6692925B1
(en)
|
1992-11-17 |
2004-02-17 |
Ludwig Institute For Cancer Research |
Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
|
|
EP1475440A3
(en)
|
1993-01-12 |
2004-11-17 |
The Johns Hopkins University School Of Medicine |
Growth differentiation factor-3
|
|
US5637480A
(en)
|
1993-05-12 |
1997-06-10 |
Genetics Institute, Inc. |
DNA molecules encoding bone morphogenetic protein-10
|
|
AU677849B2
(en)
|
1993-05-12 |
1997-05-08 |
Genetics Institute, Llc |
BMP-10 compositions
|
|
US5677196A
(en)
|
1993-05-18 |
1997-10-14 |
University Of Utah Research Foundation |
Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
|
|
US5831050A
(en)
|
1993-06-07 |
1998-11-03 |
Creative Biomolecules, Inc. |
Morphogen cell surface receptor
|
|
ATE355369T1
(de)
|
1993-10-14 |
2006-03-15 |
Harvard College |
Verfahren zur induzierung und zur erhaltung neuronalen zellen
|
|
US5525490A
(en)
|
1994-03-29 |
1996-06-11 |
Onyx Pharmaceuticals, Inc. |
Reverse two-hybrid method
|
|
US5658876A
(en)
|
1994-04-28 |
1997-08-19 |
The General Hospital Corporation |
Activin antagonists as novel contraceptives
|
|
CA2194660C
(en)
|
1994-07-08 |
2009-09-29 |
Se-Jin Lee |
Growth differentiation factor-11
|
|
US5885574A
(en)
|
1994-07-26 |
1999-03-23 |
Amgen Inc. |
Antibodies which activate an erythropoietin receptor
|
|
US5545616A
(en)
|
1994-09-22 |
1996-08-13 |
Genentech, Inc. |
Method for predicting and/or preventing preterm labor
|
|
US5760010A
(en)
|
1995-01-01 |
1998-06-02 |
Klein; Ira |
Method of treating liver disorders with a macrolide antibiotic
|
|
US5814565A
(en)
|
1995-02-23 |
1998-09-29 |
University Of Utah Research Foundation |
Integrated optic waveguide immunosensor
|
|
ATE352638T1
(de)
|
1995-04-11 |
2007-02-15 |
Gen Hospital Corp |
REVERSE ßTWO-HYBRIDß-SYSTEME
|
|
EP0771873A3
(en)
|
1995-10-27 |
1998-03-04 |
Takeda Chemical Industries, Ltd. |
Neuronal cell-specific receptor protein
|
|
GB9526131D0
(en)
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Recombinant chimeric receptors
|
|
US6004780A
(en)
|
1996-03-26 |
1999-12-21 |
Human Genome Sciences, Inc. |
Growth factor HTTER36
|
|
US20050244867A1
(en)
|
1996-03-26 |
2005-11-03 |
Human Genome Sciences, Inc. |
Growth factor HTTER36
|
|
EP0939816A1
(en)
|
1996-10-25 |
1999-09-08 |
G.D. SEARLE & CO. |
Circularly permuted erythropoietin receptor agonists
|
|
US6605699B1
(en)
|
1997-01-21 |
2003-08-12 |
Human Genome Sciences, Inc. |
Galectin-11 polypeptides
|
|
US6034062A
(en)
|
1997-03-13 |
2000-03-07 |
Genetics Institute, Inc. |
Bone morphogenetic protein (BMP)-9 compositions and their uses
|
|
US6231880B1
(en)
|
1997-05-30 |
2001-05-15 |
Susan P. Perrine |
Compositions and administration of compositions for the treatment of blood disorders
|
|
CA2297489A1
(en)
|
1997-07-30 |
1999-02-11 |
Emory University |
Novel bone mineralization proteins, dna, vectors, expression systems
|
|
US6696260B1
(en)
|
1997-08-01 |
2004-02-24 |
The Johns Hopkins University School Of Medicine |
Methods to identify growth differentiation factor (GDF) binding proteins
|
|
US6891082B2
(en)
|
1997-08-01 |
2005-05-10 |
The Johns Hopkins University School Of Medicine |
Transgenic non-human animals expressing a truncated activintype II receptor
|
|
US6656475B1
(en)
|
1997-08-01 |
2003-12-02 |
The Johns Hopkins University School Of Medicine |
Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
|
|
AU8666398A
(en)
|
1997-08-01 |
1999-02-22 |
Johns Hopkins University School Of Medicine, The |
Methods to identify growth differentiation factor (gdf) receptors
|
|
US6953662B2
(en)
|
1997-08-29 |
2005-10-11 |
Human Genome Sciences, Inc. |
Follistatin-3
|
|
EP1015468A4
(en)
|
1997-08-29 |
2000-09-06 |
Human Genome Sciences Inc |
FOLLISTATINE-3
|
|
NZ503489A
(en)
|
1997-10-03 |
2002-11-26 |
Chugai Pharmaceutical Co Ltd |
Natural humanized antibody, method of production and pharmaceutical composition
|
|
US6696411B1
(en)
|
1998-04-22 |
2004-02-24 |
Cornell Research Foundation, Inc. |
Canine erythropoietin gene and recombinant protein
|
|
CA2343268A1
(en)
|
1998-09-17 |
2000-03-23 |
Eli Lilly And Company |
Protein formulations
|
|
AU5502799A
(en)
|
1998-09-22 |
2000-04-10 |
Long Yu |
New human growth differentiation factor encoding sequence and polypeptide encoded by such dna sequence and producing method thereof
|
|
US6472179B2
(en)
|
1998-09-25 |
2002-10-29 |
Regeneron Pharmaceuticals, Inc. |
Receptor based antagonists and methods of making and using
|
|
US6548634B1
(en)
|
1998-09-30 |
2003-04-15 |
Chiron Corporation |
Synthetic peptides having FGF receptor affinity
|
|
US6238860B1
(en)
|
1998-11-05 |
2001-05-29 |
Dyax Corp. |
Binding moieties for human parvovirus B19
|
|
US6777205B1
(en)
|
1998-11-06 |
2004-08-17 |
Sterrenbeld Biotechnologie North America, Inc. |
Host cells expressing recombinant human erythropoietin
|
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
|
ATE322681T1
(de)
|
1999-01-21 |
2006-04-15 |
Metamorphix Inc |
Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen
|
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
|
CA2365449A1
(en)
|
1999-04-19 |
2000-10-26 |
Kyowa Hakko Kogyo Co., Ltd. |
Inhibitor of the growth of androgen-independent tumor
|
|
US6468543B1
(en)
|
1999-05-03 |
2002-10-22 |
Zymogenetics, Inc. |
Methods for promoting growth of bone using ZVEGF4
|
|
KR20020065517A
(ko)
|
1999-11-12 |
2002-08-13 |
맥시겐 홀딩스 리미티드 |
인터페론 감마 접합체
|
|
NZ519546A
(en)
|
1999-12-15 |
2005-07-29 |
Res Dev Foundation |
Betaglycan as an inhibin receptor and uses thereof
|
|
US20030224501A1
(en)
|
2000-03-17 |
2003-12-04 |
Young Paul E. |
Bone morphogenic protein polynucleotides, polypeptides, and antibodies
|
|
JP4487376B2
(ja)
|
2000-03-31 |
2010-06-23 |
味の素株式会社 |
腎疾患治療剤
|
|
ATE291436T2
(de)
|
2000-05-15 |
2005-04-15 |
Hoffmann La Roche |
Flüssige arzneizubereitung enthaltend ein erythropoietin derivat
|
|
US6627424B1
(en)
|
2000-05-26 |
2003-09-30 |
Mj Bioworks, Inc. |
Nucleic acid modifying enzymes
|
|
AU2001269709A1
(en)
|
2000-07-19 |
2002-02-05 |
Eli Lilly And Company |
Nucleic acids, vectors, host cells, polypeptides, and uses thereof
|
|
US6632180B1
(en)
|
2000-09-07 |
2003-10-14 |
John H. Laragh |
Method for evaluating and treating hypertension
|
|
DE10045591A1
(de)
|
2000-09-15 |
2002-04-04 |
Klaus Pfizenmaier |
Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
|
|
EP1356075A4
(en)
|
2000-10-16 |
2005-04-13 |
Compound Therapeutics Inc |
PROTEIN EQUIPMENT FOR ANTIBODY MIMETICS AND OTHER TIE PROTEINS
|
|
US7087224B2
(en)
|
2000-10-31 |
2006-08-08 |
Amgen Inc. |
Method of treating anemia by administering IL-1ra
|
|
AU2567002A
(en)
|
2000-11-20 |
2002-05-27 |
Univ Illinois |
Membrane scaffold proteins
|
|
US20030082233A1
(en)
|
2000-12-01 |
2003-05-01 |
Lyons Karen M. |
Method and composition for modulating bone growth
|
|
AU2002236558A1
(en)
|
2000-12-01 |
2002-06-11 |
Regents Of The University Of California |
Method and composition for modulating bone growth
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
TW200526779A
(en)
|
2001-02-08 |
2005-08-16 |
Wyeth Corp |
Modified and stabilized GDF propeptides and uses thereof
|
|
US20040132675A1
(en)
|
2002-02-08 |
2004-07-08 |
Calvin Kuo |
Method for treating cancer and increasing hematocrit levels
|
|
US7294472B2
(en)
|
2001-03-14 |
2007-11-13 |
Caden Biosciences |
Method for identifying modulators of G protein coupled receptor signaling
|
|
EP1369130A1
(en)
|
2001-03-16 |
2003-12-10 |
Takeda Chemical Industries, Ltd. |
Process for producing sustained release preparation
|
|
US20030082630A1
(en)
|
2001-04-26 |
2003-05-01 |
Maxygen, Inc. |
Combinatorial libraries of monomer domains
|
|
PL403488A1
(pl)
|
2001-05-24 |
2013-07-08 |
Zymogenetics, Inc. |
Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulina
|
|
WO2002094864A2
(en)
|
2001-05-25 |
2002-11-28 |
Genset S.A. |
Human cdnas and proteins and uses thereof
|
|
AUPR638101A0
(en)
|
2001-07-13 |
2001-08-09 |
Bioa Pty Limited |
Composition and method for treatment of disease
|
|
EP1416273B1
(en)
|
2001-07-17 |
2009-11-11 |
Teijin Limited |
Method of selecting substance characterized by assaying ppard activating effect and drug
|
|
US6855344B2
(en)
|
2001-07-17 |
2005-02-15 |
Integrated Chinese Medicine Holdings, Ltd. |
Compositions and methods for prostate and kidney health and disorders, an herbal preparation
|
|
KR100453877B1
(ko)
|
2001-07-26 |
2004-10-20 |
메덱스젠 주식회사 |
연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
|
|
US7320789B2
(en)
|
2001-09-26 |
2008-01-22 |
Wyeth |
Antibody inhibitors of GDF-8 and uses thereof
|
|
US6784154B2
(en)
|
2001-11-01 |
2004-08-31 |
University Of Utah Research Foundation |
Method of use of erythropoietin to treat ischemic acute renal failure
|
|
EP1487472B1
(en)
|
2001-12-06 |
2019-06-26 |
Fibrogen, Inc. |
Treatment of ischemic or hypoxic conditions using heterocyclic carboxamides
|
|
US20060234918A1
(en)
|
2001-12-19 |
2006-10-19 |
Voyager Pharmaceutical Corporation |
Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors
|
|
US20030144203A1
(en)
|
2001-12-19 |
2003-07-31 |
Voyager Pharmaceutical Corporation |
Methods for slowing senescence and treating and preventing diseases associated with senescence
|
|
US6998118B2
(en)
|
2001-12-21 |
2006-02-14 |
The Salk Institute For Biological Studies |
Targeted retrograde gene delivery for neuronal protection
|
|
AU2003216250A1
(en)
|
2002-02-11 |
2003-09-04 |
Genentech, Inc. |
Antibody variants with faster antigen association rates
|
|
AU2003216345A1
(en)
|
2002-02-21 |
2003-09-09 |
Wyeth |
Follistatin domain containing proteins
|
|
WO2003072715A2
(en)
|
2002-02-21 |
2003-09-04 |
Wyeth |
Gasp1: a follistatin domain containing protein
|
|
US20030219846A1
(en)
|
2002-02-28 |
2003-11-27 |
Pfizer Inc. |
Assay for activity of the ActRIIB kinase
|
|
AU2003232485A1
(en)
|
2002-04-18 |
2003-10-27 |
Mtm Laboratories Ag |
Neopeptides and methods useful for detection and treatment of cancer
|
|
DE10234192B4
(de)
|
2002-07-26 |
2009-11-26 |
Epoplus Gmbh Co.Kg |
Verwendung von Erythropoetin
|
|
KR20050083635A
(ko)
|
2002-08-16 |
2005-08-26 |
와이어쓰 |
Ｂｍｐ-2 에스트로겐 반응 요소 및 이의 사용 방법
|
|
CA2501936A1
(en)
|
2002-10-15 |
2004-04-29 |
Celgene Corporation |
Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
|
|
US7261893B2
(en)
|
2002-10-22 |
2007-08-28 |
Wyeth |
Neutralizing antibodies against GDF-8 and uses therefor
|
|
US20040223966A1
(en)
|
2002-10-25 |
2004-11-11 |
Wolfman Neil M. |
ActRIIB fusion polypeptides and uses therefor
|
|
AU2002953327A0
(en)
|
2002-12-12 |
2003-01-09 |
Monash University |
Methods of diagnosing prognosing and treating activin associated diseases and conditions
|
|
WO2004064770A2
(en)
|
2003-01-17 |
2004-08-05 |
Government Of The United States Of America As Represented By The Secretary, Department Of Health Andhuman Services |
Use of smad3 inhibitor in the treatment of fibrosis dependent on epithelial to mesenchymal transition as in the eye and kidney
|
|
NZ541593A
(en)
|
2003-02-07 |
2009-05-31 |
Prometic Biosciences Inc |
Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis
|
|
US20040197828A1
(en)
|
2003-03-26 |
2004-10-07 |
Gaddy Dana P. |
Method for diagnosis and treatment of bone turnover
|
|
WO2010019832A2
(en)
|
2008-08-13 |
2010-02-18 |
Designer Molecules, Inc. |
Amide-extended crosslinking compounds and methods for use thereof
|
|
US20070184052A1
(en)
|
2003-05-09 |
2007-08-09 |
Lin Herbert Y |
Soluble tgf-b type III receptor fusion proteins
|
|
KR20060026860A
(ko)
|
2003-06-02 |
2006-03-24 |
와이어쓰 |
신경근 장애의 치료를 위한, 코르티코스테로이드와 조합된미오스타틴 (ｇｄｆ８) 저해제의 용도
|
|
CA2529623A1
(en)
|
2003-06-16 |
2005-02-17 |
Celltech R & D, Inc. |
Antibodies specific for sclerostin and methods for increasing bone mineralization
|
|
US7611465B2
(en)
*
|
2003-07-15 |
2009-11-03 |
Board Of Regents, The University Of Texas System |
Rapid and accurate detection of bone quality using ultrasound critical angle reflectometry
|
|
WO2005009460A2
(en)
|
2003-07-25 |
2005-02-03 |
Medexis, S.A. |
Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer
|
|
DE10335211A1
(de)
|
2003-08-01 |
2005-02-17 |
Robert Bosch Gmbh |
Kraftstoff-Einspritzvorrichtung für eine Brennkraftmaschine
|
|
US20070135336A1
(en)
|
2003-09-15 |
2007-06-14 |
De Kretser David |
Follistatin isoforms and uses thereof
|
|
US8895540B2
(en)
|
2003-11-26 |
2014-11-25 |
DePuy Synthes Products, LLC |
Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
|
|
JP4987484B2
(ja)
|
2004-01-22 |
2012-07-25 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
補体結合が低下した抗癌抗体
|
|
US20050197292A1
(en)
|
2004-01-30 |
2005-09-08 |
Glennda Smithson |
Compositions and methods for treating T-cell mediated pathological conditions
|
|
CA2561317A1
(en)
|
2004-03-26 |
2005-10-13 |
Acceleron Pharma Inc. |
Bmp-3 propeptides and related methods
|
|
US7459527B2
(en)
|
2004-03-31 |
2008-12-02 |
Xencor, Inc. |
BMP-7 variants with improved properties
|
|
US7741284B2
(en)
|
2004-05-12 |
2010-06-22 |
Acceleron Pharma Inc. |
BMP10 propeptides and related methods
|
|
EP1771557B1
(en)
|
2004-06-24 |
2014-12-31 |
Acceleron Pharma Inc. |
GDF3 Propeptides and Related Methods
|
|
EP1771470B1
(en)
|
2004-07-23 |
2013-06-26 |
Acceleron Pharma Inc. |
Actrii receptor polypeptides, methods and compositions
|
|
US8617815B2
(en)
|
2004-08-05 |
2013-12-31 |
The Regents Of The University Of California |
Molecules with effects on cellular development and function
|
|
WO2006020884A2
(en)
|
2004-08-12 |
2006-02-23 |
Wyeth |
Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors
|
|
US8435948B2
(en)
|
2004-09-29 |
2013-05-07 |
Mount Sinai School Of Medicine Of New York University |
Methods for inhibiting osteoclastic bone resorption and bone loss comprising administration of an anti-FSH or anti-FSHR antibody
|
|
US7879569B2
(en)
|
2004-11-09 |
2011-02-01 |
The Trustees Of The University Of Pennsylvania |
Methods for diagnosis of myelodysplastic syndromes (MDS)
|
|
US20060234299A1
(en)
|
2004-11-16 |
2006-10-19 |
Avidia Research Institute |
Protein scaffolds and uses thereof
|
|
NZ538097A
(en)
|
2005-02-07 |
2006-07-28 |
Ovita Ltd |
Method and compositions for improving wound healing
|
|
CA2597925A1
(en)
|
2005-02-16 |
2006-08-24 |
The General Hospital Corporation |
Use of a human hemojuvelin product to regulate hepcidin-mediated iron metabolism
|
|
KR20080003929A
(ko)
|
2005-04-26 |
2008-01-08 |
아지노모토 가부시키가이샤 |
골수 적혈구 전구 세포 분화 촉진제
|
|
JP2007099764A
(ja)
|
2005-09-09 |
2007-04-19 |
Ajinomoto Co Inc |
血糖低下剤
|
|
PT1931697E
(pt)
|
2005-09-28 |
2010-12-06 |
Zymogenetics Inc |
Antagonistas de il-17a e il-17f e processos para a sua utilização
|
|
US8067562B2
(en)
|
2005-11-01 |
2011-11-29 |
Amgen Inc. |
Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
|
|
US8128933B2
(en)
|
2005-11-23 |
2012-03-06 |
Acceleron Pharma, Inc. |
Method of promoting bone growth by an anti-activin B antibody
|
|
CA2856436A1
(en)
|
2005-12-06 |
2007-06-14 |
Amgen Inc. |
Uses of myostatin antagonists
|
|
JP2009519984A
(ja)
|
2005-12-20 |
2009-05-21 |
メルク フロスト カナダ リミテツド |
ステアロイル−補酵素δ−９デサチュラーゼ阻害剤としての芳香族複素環化合物
|
|
CA2634940A1
(en)
|
2005-12-21 |
2007-07-05 |
Schering Corporation |
Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
|
|
WO2007076127A2
(en)
|
2005-12-22 |
2007-07-05 |
Biogen Idec Ma Inc |
Condensed imidazoles or pyrazoles and their use as transforming growth factor modulators
|
|
JP4925364B2
(ja)
|
2006-01-20 |
2012-04-25 |
ベックマン コールター， インコーポレイテッド |
鉄欠乏を検出する方法
|
|
US7820721B2
(en)
|
2006-01-25 |
2010-10-26 |
Wellstat Therapeutics Corporation |
Compounds for the treatment of metabolic disorders
|
|
CN101394738A
(zh)
|
2006-02-28 |
2009-03-25 |
维尔斯达医疗公司 |
用于治疗代谢紊乱的化合物
|
|
US8008074B2
(en)
*
|
2006-03-20 |
2011-08-30 |
The Uab Research Foundation |
Compositions and methods for improving bone mass through modulation of receptors of PTH and fragments thereof
|
|
EP2007813A2
(en)
|
2006-04-14 |
2008-12-31 |
Amgen Inc. |
Agonist erythropoietin receptor antibodies
|
|
WO2007123391A1
(en)
|
2006-04-20 |
2007-11-01 |
Academisch Ziekenhuis Leiden |
Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
|
|
WO2007133653A2
(en)
|
2006-05-09 |
2007-11-22 |
Hemaquest Pharmaceuticals, Inc. |
Methods for treating blood disorders
|
|
NZ574331A
(en)
|
2006-07-21 |
2011-01-28 |
Lyne Lab |
Liquid compositions of calcium acetate
|
|
GB0615129D0
(en)
|
2006-07-29 |
2006-09-06 |
Univ Cardiff |
Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies
|
|
WO2008030367A2
(en)
|
2006-09-01 |
2008-03-13 |
The General Hospital Corporation |
Selective myostatin inhibitors
|
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
|
US7547781B2
(en)
|
2006-09-11 |
2009-06-16 |
Curis, Inc. |
Quinazoline based EGFR inhibitors containing a zinc binding moiety
|
|
JP5468187B2
(ja)
|
2006-09-26 |
2014-04-09 |
ポリプラスチックス株式会社 |
ポリアセタール樹脂組成物
|
|
WO2008060139A1
(en)
|
2006-11-17 |
2008-05-22 |
Erasmus University Medical Center Rotterdam |
Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein
|
|
US20100003190A1
(en)
|
2006-12-08 |
2010-01-07 |
Caritas St. Elizabeth's Medical Center Of Boston, Inc. |
Method for protecting renal tubular epithelial cells from radiocontrast nephropathy (RCN)
|
|
WO2008072723A1
(ja)
|
2006-12-14 |
2008-06-19 |
Forerunner Pharma Research Co., Ltd. |
抗Claudin3モノクローナル抗体およびそれを用いる癌の治療および診断
|
|
US8895016B2
(en)
|
2006-12-18 |
2014-11-25 |
Acceleron Pharma, Inc. |
Antagonists of activin-actriia and uses for increasing red blood cell levels
|
|
MX2009006651A
(es)
|
2006-12-18 |
2009-08-26 |
Acceleron Pharma Inc |
Antagonistas de activina-actrii y usos para incrementar los niveles de globulos rojo.
|
|
US20100028332A1
(en)
|
2006-12-18 |
2010-02-04 |
Acceleron Pharma Inc. |
Antagonists of actriib and uses for increasing red blood cell levels
|
|
KR101526613B1
(ko)
|
2007-02-01 |
2015-06-26 |
악셀레론 파마 인코포레이티드 |
액티빈-ａｃｔｒⅱａ 길항제 및 유방암을 치료 또는 예방하기 위한 이들의 용도
|
|
TW201940502A
(zh)
|
2007-02-02 |
2019-10-16 |
美商艾瑟勒朗法瑪公司 |
衍生自ＡｃｔＲＩＩＢ的變體與其用途
|
|
TW201808334A
(zh)
|
2007-02-09 |
2018-03-16 |
艾瑟勒朗法瑪公司 |
包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途
|
|
US8501678B2
(en)
|
2007-03-06 |
2013-08-06 |
Atara Biotherapeutics, Inc. |
Variant activin receptor polypeptides and uses thereof
|
|
TWI454479B
(zh)
|
2007-03-06 |
2014-10-01 |
Amgen Inc |
變異之活動素受體多肽及其用途
|
|
WO2008151078A1
(en)
|
2007-06-01 |
2008-12-11 |
Wyeth |
Methods and compositions for modulating bmp-10 activity
|
|
WO2009009059A1
(en)
|
2007-07-09 |
2009-01-15 |
Biogen Idec Ma Inc. |
Spiro compounds as antagonists of tgf-beta
|
|
JP2010535708A
(ja)
|
2007-08-03 |
2010-11-25 |
ビオマリン アイジーエー リミテッド |
デュシェンヌ型筋ジストロフィーの治療のための薬物併用
|
|
GB0715087D0
(en)
|
2007-08-03 |
2007-09-12 |
Summit Corp Plc |
Drug combinations for the treatment of duchenne muscular dystrophy
|
|
GB0715938D0
(en)
|
2007-08-15 |
2007-09-26 |
Vastox Plc |
Method of treatment of duchenne muscular dystrophy
|
|
WO2009025651A1
(en)
|
2007-08-17 |
2009-02-26 |
University Of Maine System Board Of Trustees |
Biologically active peptide and method of using the same
|
|
US20100279409A1
(en)
|
2007-09-13 |
2010-11-04 |
Neil Robson |
Method for modifying celluar immune resonse by modulating activin activity
|
|
EP2207562B1
(en)
|
2007-09-18 |
2017-05-31 |
Acceleron Pharma, Inc. |
Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
|
|
PE20091163A1
(es)
|
2007-11-01 |
2009-08-09 |
Wyeth Corp |
Anticuerpos para gdf8
|
|
JP5583591B2
(ja)
|
2007-11-21 |
2014-09-03 |
アムジエン・インコーポレーテツド |
Ｗｉｓｅ結合抗体及びエピトープ
|
|
EP2265603B1
(en)
|
2008-03-13 |
2014-05-07 |
The General Hospital Corporation |
Inhibitors of the bmp signaling pathway
|
|
US8814094B2
(en)
|
2008-04-04 |
2014-08-26 |
Tactair Fluid Controls, Inc. |
Locking mechanism with bi-modal actuator
|
|
EP2283119B1
(en)
|
2008-05-06 |
2015-01-07 |
Joslin Diabetes Center, Inc. |
Methods and compositions for inducing brown adipogenesis
|
|
WO2009137075A1
(en)
|
2008-05-06 |
2009-11-12 |
Acceleron Pharma Inc. |
Anti-activin antibodies and uses for promoting bone growth
|
|
JP2011521969A
(ja)
|
2008-05-30 |
2011-07-28 |
スムマ ヘルス システムズ エルエルシー |
眼疾患を治療するためのＴＧＦ−β受容体阻害剤又はアクチビン様キナーゼ（ＡＬＫ）５阻害剤、Ａ−８３−０１及びＳＢ−４３１５４２の使用方法及び創傷治療条件
|
|
WO2009158033A2
(en)
*
|
2008-06-26 |
2009-12-30 |
Acceleron Pharma Inc. |
Antagonists of activin-actriia and uses for increasing red blood cell levels
|
|
EP3415161A1
(en)
|
2008-06-26 |
2018-12-19 |
Acceleron Pharma Inc. |
The use of an actriib antagonist for the treatment of anemia
|
|
HUE063136T2
(hu)
|
2008-08-14 |
2023-12-28 |
Acceleron Pharma Inc |
GDF-Csapdák
|
|
US8216997B2
(en)
|
2008-08-14 |
2012-07-10 |
Acceleron Pharma, Inc. |
Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
|
|
WO2010059861A1
(en)
|
2008-11-20 |
2010-05-27 |
University Of Southern California |
Compositions and methods to modulate hair growth
|
|
EA201100832A1
(ru)
|
2008-11-26 |
2011-12-30 |
Амген Инк. |
Варианты полипептидов рецептора iib активина и их применение
|
|
CA2749544A1
(en)
|
2009-01-13 |
2010-07-22 |
Acceleron Pharma Inc. |
Methods for increasing adiponectin
|
|
CN102307598A
(zh)
*
|
2009-02-05 |
2012-01-04 |
迪格纳生物技术公司 |
TGF-β1抑制肽的药物制剂
|
|
US8110355B2
(en)
|
2009-02-20 |
2012-02-07 |
GenRemedy, LLC |
Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis
|
|
JP2012524073A
(ja)
|
2009-04-17 |
2012-10-11 |
スムマ ヘルス システムズ エルエルシー |
眼球瘢痕化を抑制するための形質転換成長因子−β受容体阻害剤の使用
|
|
EA027071B1
(ru)
|
2009-04-27 |
2017-06-30 |
Новартис Аг |
АНТИТЕЛО К ActRIIB И СОДЕРЖАЩАЯ ЕГО КОМПОЗИЦИЯ
|
|
KR20120049214A
(ko)
|
2009-06-08 |
2012-05-16 |
악셀레론 파마 인코포레이티드 |
발열성 지방세포를 증가시키는 방법
|
|
US8293881B2
(en)
|
2009-06-12 |
2012-10-23 |
Acceleron Pharma Inc. |
Isolated nucleic acid encoding a truncated ActRIIB fusion protein
|
|
KR102170682B1
(ko)
|
2009-08-13 |
2020-10-28 |
악셀레론 파마 인코포레이티드 |
적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용
|
|
BR112012005225B8
(pt)
|
2009-09-09 |
2023-01-10 |
Acceleron Pharma Inc |
Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente
|
|
EP2496247B1
(en)
|
2009-11-03 |
2017-08-23 |
Acceleron Pharma, Inc. |
Methods for treating fatty liver disease
|
|
WO2011063018A1
(en)
|
2009-11-17 |
2011-05-26 |
Acceleron Pharma Inc. |
Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
|
|
WO2012027065A2
(en)
|
2010-08-27 |
2012-03-01 |
Celgene Corporation |
Combination therapy for treatment of disease
|
|
US8580922B2
(en)
|
2011-03-04 |
2013-11-12 |
Shire Human Genetic Therapies, Inc. |
Peptide linkers for polypeptide compositions and methods for using same
|
|
ES2692519T3
(es)
|
2011-07-01 |
2018-12-04 |
Novartis Ag |
Método para tratar trastornos metabólicos
|
|
KR20220075438A
(ko)
|
2011-10-17 |
2022-06-08 |
악셀레론 파마 인코포레이티드 |
비효율적 적혈구생성 치료를 위한 방법 및 조성물
|
|
US8765385B2
(en)
|
2011-10-27 |
2014-07-01 |
Ravindra Kumar |
Method of detection of neutralizing anti-actriib antibodies
|
|
WO2013063536A1
(en)
|
2011-10-27 |
2013-05-02 |
Acceleron Pharma, Inc. |
Actriib binding agents and uses thereof
|
|
US20140303068A1
(en)
|
2011-10-28 |
2014-10-09 |
Paranta Biosciences Limited |
Method of treating mucus hypersecretion
|
|
PE20142114A1
(es)
|
2011-12-19 |
2015-01-04 |
Amgen Inc |
Polipeptidos de receptores de activina variantes, solos o en combinacion con quimioterapia, y sus usos
|
|
EP2830642B1
(en)
|
2012-03-30 |
2019-08-28 |
Shire Human Genetic Therapies, Inc. |
Subcutaneous administration of iduronate- 2-sulfatase
|
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
|
EP2861620A2
(en)
|
2012-06-14 |
2015-04-22 |
The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center |
Use of blocking agents of bone morphogenie protein (bmp) signaling for the treatment of neuroinflammatory and neurodegenerative diseases
|
|
EP2868667B1
(en)
|
2012-07-02 |
2019-01-30 |
Kyowa Hakko Kirin Co., Ltd. |
Therapeutic agent for anemia including renal anemia and cancer-induced anemia which contains anti-bmp9 antibody as active ingredient
|
|
AU2013334660B2
(en)
|
2012-10-24 |
2018-08-09 |
Celgene Corporation |
Methods for treating anemia
|
|
WO2014066486A2
(en)
|
2012-10-24 |
2014-05-01 |
Celgene Corporation |
Biomarker for use in treating anemia
|
|
WO2014064292A1
(en)
|
2012-10-26 |
2014-05-01 |
Universite Pierre Et Marie Curie (Paris 6) |
A method for preventing or treating atrial fibrillation
|
|
MX366336B
(es)
|
2012-11-02 |
2019-07-05 |
Celgene Corp |
Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros.
|
|
ES3023054T3
(en)
|
2012-11-08 |
2025-05-29 |
Clearside Biomedical Inc |
Methods for the treatment of ocular disease in human subjects
|
|
CN103047581B
(zh)
|
2012-12-04 |
2015-04-01 |
京东方科技集团股份有限公司 |
背光模组及具有该背光模组的显示装置
|
|
WO2014093531A1
(en)
|
2012-12-11 |
2014-06-19 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Modulation of myofiber repair by anti-myostatin in strategies with stem cells
|
|
US20140220033A1
(en)
|
2013-02-01 |
2014-08-07 |
Santa Maria Biotherapeutics, Inc. |
Administration of an Anti-Activin-A Compound to a Subject
|
|
TWI655207B
(zh)
|
2013-07-30 |
2019-04-01 |
再生元醫藥公司 |
抗活化素ａ之抗體及其用途
|
|
AU2014307589A1
(en)
|
2013-08-14 |
2016-02-11 |
Novartis Ag |
Methods of treating sporadic inclusion body myositis
|
|
CA2932463A1
(en)
|
2013-12-16 |
2015-06-25 |
Paranta Biosciences Limited |
Method of diagnosis and treatment
|
|
HK1231513A1
(zh)
|
2014-01-14 |
2017-12-22 |
Santa Maria Biotherapeutics, Inc. |
活化素抑制劑應答預測和用於治療的用途
|
|
US20170248609A1
(en)
|
2014-01-27 |
2017-08-31 |
Novartis Ag |
Biomarkers predictive of muscle atrophy, method and use
|
|
US20160046690A1
(en)
|
2014-03-21 |
2016-02-18 |
Acceleron Pharma, Inc. |
Methods for increasing red blood cell levels and treating ineffective erythropoiesis
|
|
US10260068B2
(en)
|
2014-03-31 |
2019-04-16 |
Sumitomo Dainippon Pharma Co., Ltd. |
Prophylactic agent and therapeutic agent for fibrodysplasia ossificans progressiva
|
|
JP6649895B2
(ja)
|
2014-04-18 |
2020-02-19 |
アクセルロン ファーマ， インコーポレイテッド |
赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法
|
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
|
TN2016000553A1
(en)
|
2014-06-13 |
2018-04-04 |
Acceleron Pharma Inc |
Methods and compositions for treating ulcers
|
|
EA201692568A1
(ru)
|
2014-06-13 |
2017-05-31 |
Санта Мария Биотерапевтикс, Инк. |
Составы с полипептидами-рецепторами и связанные с ними способы
|
|
MA41052A
(fr)
|
2014-10-09 |
2017-08-15 |
Celgene Corp |
Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
|
|
MA41119A
(fr)
|
2014-12-03 |
2017-10-10 |
Acceleron Pharma Inc |
Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
|
|
IL252631B2
(en)
|
2014-12-03 |
2024-06-01 |
Celgene Corp |
ACTIVIN-ACTRII antagonists and uses for the treatment of anemia
|
|
JOP20160092B1
(ar)
|
2015-05-13 |
2023-03-28 |
Celgene Corp |
علاج البيتا ثلاسيميا باستخدام مصطبة لجائنية
|
|
EP3298034A4
(en)
|
2015-05-20 |
2019-02-13 |
Celgene Corporation |
IN VITRO CELL CULTURE PROCEDURE FOR BETA THALASSEMIA BY MEANS OF ACTIVIN TYPE II RECEPTOR LIGANDS
|
|
EP4218792A1
(en)
|
2015-08-04 |
2023-08-02 |
Acceleron Pharma Inc. |
Composition for treating myeloproliferative disorders
|
|
US11123430B2
(en)
|
2015-11-04 |
2021-09-21 |
Acceleron Pharma Inc. |
Methods for increasing red blood cell levels and treating ineffective erythropoiesis
|
|
CN108697793B
(zh)
|
2015-11-23 |
2023-08-01 |
阿塞勒隆制药公司 |
治疗眼睛疾病的方法
|
|
HUE067225T2
(hu)
|
2016-07-27 |
2024-10-28 |
Acceleron Pharma Inc |
Mielofibrózis kezelésére szolgáló készítmények
|
